Our group has shed light on mechanisms of progression from bone marrow failure syndromes to myeloid neoplasia (Gurnari et al, JCO 2023) and has been pioneer in the molecular diagnosis of VEXAS, a new disorder discovered only in 2020 (Gurnari et al AJH 2024).